Drug Index


Mechanism :

Ceftibuten exerts its bactericidal action by binding to essential target proteins of the bacterial cell wall. This binding leads to inhibition of cell-wall synthesis.
Ceftibuten is stable in the presence of most plasmid-mediated beta-lactamases, but it is not stable in the presence of chromosomally-mediated cephalosporinases produced in organisms such as Bacteroides, Citrobacter, Enterobacter, Morganella, and Serratia. Like other beta-lactam agents, ceftibuten should not be used against strains resistant to beta-lactams due to general mechanisms such as permeability or penicillin-binding protein changes like penicillin-resistant S. pneumoniae.

Indication :

  • Otitis Media
  • Pharyngitis and Tonsillitis

Contraindications :

Ceftibuten is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

Dosing :

<6 months:
Safety and efficacy not established.
6-12 years or <45 kg:
9 mg/kg (Oral) OD daily; 400 mg/day (Oral) for maximum of 10 days
>12 years or >45 kg:
(Adult doses) 400 mg (Oral) OD daily for 10 days.

Adverse Effect :

Nausea, headache, diarrhea, dyspepsia, dizziness, abdominal pain, vomiting, anorexia, constipation, dry mouth, dyspnea, dysuria, eructation, fatigue, flatulence, paresthesia, pruritus, rash, somnolence, taste perversion, urticaria.

Interaction :

Theophylline: The pharmacokinetics of theophylline were not altered. The effect of ceftibuten on the pharmacokinetics of theophylline administered orally has not been investigated.
Drug/Laboratory Test Interactions: There have been no chemical or laboratory test interactions with ceftibuten noted to date. False-positive direct Coombs tests have been reported during treatment with other cephalosporins. Therefore, it should be recognized that a positive Coombs test could be due to the drug. The results of assays using red cells from healthy subjects to determine whether ceftibuten would cause direct Coombs reactions in vitro showed no positive reaction at ceftibuten concentrations as high as 40 µg/mL.

Hepatic Dose :

No dosage adjustments are recommended.
01/23/2024 11:16:23 Ceftibuten
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0